Visualization and Tissue Distribution of α1L-Adrenoceptor in Human Prostate by the Fluorescently Labeled Ligand Alexa-488-Silodosin

Journal of Urology

Volumn 183, Issue 2, 2010, Pages 812-819

  Morishima, Shigeru ^a   Suzuki, Fumiko ^a   Nishimune, Atsushi ^a   Yoshiki, Hatsumi ^a   Akino, Hironobu ^a,b   Yokoyama, Osamu ^a,b   Muramatsu, Ikunobu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

^b University of Fukui   (Japan)

Author keywords

adrenergic; alpha 1; fluorescent dyes; KMD 3213; prostate; prostatic hyperplasia; receptors

Indexed keywords

ADRENERGIC RECEPTOR; ALEXA FLUOR 488; ALPHA1A ADRENOCEPTOR; ALPHA1L ADRENOCEPTOR; PRAZOSIN; SILODOSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHO CELL; CONFOCAL MICROSCOPY; DRUG PROTEIN BINDING; FLUORESCENCE; HUMAN; HUMAN TISSUE; NONHUMAN; PRIORITY JOURNAL; PROSTATE; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; RADIOASSAY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; FLUORESCENCE; FLUOROBENZENES; INDOLES; MALE; PROSTATE; RECEPTORS, ADRENERGIC, ALPHA-1; TISSUE DISTRIBUTION;

EID: 73749085043     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.09.078     Document Type: Article

References (23)

1. Andersson K.E. Alpha-adrenoceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoceptor antagonists. World J Urol 19 (2002) 390
2. Alexander S.P., Mathie A., and Peters J.A. Guide to receptors and channels (GRAC), 3rd edition. Br J Pharmacol 153 suppl. (2008) S1
3. Hiraizumi-Hiraoka Y., Tanaka T., Yamamoto H., et al. Identification of alpha-1L adrenoceptor in rabbit ear artery. J Pharmacol Exp Ther 310 (2004) 995
4. Gray K., Short J., and Ventura S. The alpha1A-adrenoceptor gene is required for the alpha1L-adrenoceptor-mediated response in isolated preparations of the mouse prostate. Br J Pharmacol 155 (2008) 103
5. Morishima S., Tanaka T., Yamamoto H., et al. Identification of alpha-1L and alpha-1A adrenoceptors in human prostate by tissue segment binding. J Urol 177 (2007) 377
6. Flavahan N.A., and Vanhoutte P.M. Alpha-1 and alpha-2 adrenoceptor: response coupling in canine saphenous and femoral veins. J Pharmacol Exp Ther 238 (1986) 131
7. Muramatsu I., Ohmura T., Kigoshi S., et al. Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle. Br J Pharmacol 99 (1990) 197
8. Ford A.P., Arredondo N.F., Blue Jr. D.R., et al. RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. Mol Pharmacol 49 (1996) 209
9. Muramatsu I., Morishima S., Suzuki F., et al. Identification of alpha 1L-adrenoceptor in mice and its abolition by alpha 1A-adrenoceptor gene knockout. Br J Pharmacol 155 (2008) 1224
10. Morishima S., Suzuki F., Yoshiki H., et al. Identification of the alpha(1L)-adrenoceptor in rat cerebral cortex and possible relationship between alpha(1L)- and alpha(1A)-adrenoceptors. Br J Pharmacol 153 (2008) 1485
11. Murata S., Taniguchi T., and Muramatsu I. Pharmacological analysis of the novel, selective alpha1-adrenoceptor antagonist, KMD-3213, and its suitability as a tritiated radioligand. Br J Pharmacol 127 (1999) 19
12. Murata S., Taniguchi T., Takahashi M., et al. Tissue selectivity of KMD-3213, an alpha(1)-adrenoreceptor antagonist, in human prostate and vasculature. J Urol 164 (2000) 578
13. Kawabe K., Yoshida M., and Homma Y. Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men. BJU Int 98 (2006) 1019
14. Takahashi M., Taniguchi T., Kanamaru H., et al. Pharmacological characterization of [3H]-JTH-601, a novel alpha1-adrenoceptor antagonist: binding to recombinant human alpha1-adrenoceptors and human prostates. Life Sci 67 (2000) 2443
15. Muramatsu I., Tanaka T., Suzuki F., et al. Quantifying receptor properties: the tissue segment binding method-a powerful tool for the pharmacome analysis of native receptors. J Pharmacol Sci 98 (2005) 331
16. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099
17. McGrath J.C., Mackenzie J.F., and Daly C.J. Pharmacological implications of cellular localization of alpha1-adrenoceptors in native smooth muscle cells. J Auton Pharmacol 19 (1999) 303
18. Mackenzie J.F., Daly C.J., Pediani J.D., et al. Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites. J Pharmacol Exp Ther 294 (2000) 434
19. Guan Y., Xu M., Liang Z., et al. Heterogeneous transportation of alpha1B-adrenoceptor in living cells. Biophys Chem 127 (2007) 149
20. Berlier J.E., Rothe A., Buller G., et al. Quantitative comparison of long-wavelength Alexa Fluor dyes to Cy dyes: fluorescence of the dyes and their bioconjugates. J Histochem Cytochem 51 (2003) 1699
21. Muramatsu I., Suzuki F., Nishimune A., et al. Expression of distinct alpha1- adrenoceptor phenotypes in the iris of pigmented and albino rabbits. Br J Pharmacol 158 (2009) 354
22. Walden P.D., Gerardi C., and Lepor H. Localization and expression of the alpha1A-1, alpha1B and alpha1D-adrenoceptors in hyperplastic and nonhyperplastic human prostate. J Urol 161 (1999) 635
23. Shapiro E., Becich M.J., Hartanto V., et al. The relative proportion of stromal and epithelial hyperplasia is related to the development of symptomatic benign prostate hyperplasia. J Urol 147 (1992) 1293